Debt reduction plan execution (Q4 FY26)
Expected: Q4 FY26MEDIUM confidence
Targeting lower interest burden through asset monetization or strategic partnerships.
“Interest burden up 57% YoY to ₹6.28 cr; debt-to-EBITDA at 5.22x”
Sudarshan Pharma Industries Ltd: Is It a Deep Value Opportunity?
Weak
As of Mar 28, 2026, Sudarshan Pharma Industries Ltd (Trading) has a deep value score of 30/100 (rated Weak).
PE: Mid ContractionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
📊Debt increased 28% YoY — leverage rising
🌐FII stake increased 7.7% this quarter
💰Trading 51% above estimated fair value — significant premium
Re-Rating Catalysts
1. Debt reduction plan execution (Q4 FY26)
Q4 FY26MEDIUM
2. Margin recovery from operational improvements (Q1-Q2 FY27)
Q1-Q2 FY27MEDIUM
3. Strategic investor entry (Q2 FY27)
Q2 FY27LOW
Value Trap Risks
1. Debt spiral risk
HIGH2. Structural margin pressure
MEDIUM3. Working capital trap
MEDIUMKey Numbers
PAT Growth YoY
+44%
Stable
Revenue YoY
+45%
Stable
Operating Margin
6.5%
-42 bps YoY
PE Ratio
27.5
Current Price
₹24
3Y PAT CAGR
+47%
Valuation
Significantly OvervaluedIs Sudarshan Pharma Industries Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Rapid revenue growth (38.9% YoY) combined with potential debt reduction could unlock value as interest costs decline and operational efficiencies improve.
Verdict
EARLY_INNINGS
What Could Re-Rate Sudarshan Pharma Industries Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Margin recovery from operational improvements (Q1-Q2 FY27)
Expected: Q1-Q2 FY27MEDIUM confidence
Cost optimization initiatives to reverse gross margin decline from 6.60% to 3.64% YoY.
“Gross margin declined to 3.64% from 6.60% YoY”
Strategic investor entry (Q2 FY27)
Expected: Q2 FY27LOW confidence
Potential for private equity interest given undervaluation and growth trajectory.
“Market cap around ₹463-475 cr trading near 52-week lows”
What Are the Value Trap Risks for Sudarshan Pharma Industries Ltd?
Risks that could prevent re-rating or deepen the value trap
Debt spiral risk
HIGHFurther revenue slowdown or interest rate hikes
Management view: Company is actively working on debt reduction plans per investor presentation
Monitor: Debt-to-EBITDA ratio
Structural margin pressure
MEDIUMContinued input cost inflation or pricing pressure
Management view: Management focusing on higher-margin product lines per con-call
Monitor: Gross margin trend
Working capital trap
MEDIUMInventory buildup or receivables extension
Management view: Company claims working capital management is improving
Monitor: Working capital days
What Is Sudarshan Pharma Industries Ltd's Management Guidance?
Forward-looking targets from management for FY27
Management Tone: CAUTIOUS
Key Milestones
• Debt reduction target
• Margin improvement initiatives
How Fast Is Sudarshan Pharma Industries Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +45% | +12% | Stable |
| PAT (Net Profit) | +44% | +47% | Stable |
| OPM | 6.5% | -42 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Other Deep Value Stocks in Trading
Frequently Asked Questions: Sudarshan Pharma Industries Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Sudarshan Pharma Industries Ltd's deep value score?
Sudarshan Pharma Industries Ltd has a deep value score of 30/100 (rated Weak). This score is calculated from three components
- Earnings Score: 0/40 — measures PAT growth momentum across quarters
- Underperformance Score: 0/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 0/25 — operational quality (margins, revenue growth, valuation)
Is Sudarshan Pharma Industries Ltd fundamentally improving?
Sudarshan Pharma Industries Ltd's quarterly profit (PAT) growth trajectory
- Insufficient PAT data to assess improvement trend
Why is Sudarshan Pharma Industries Ltd underperforming despite good earnings?
Sudarshan Pharma Industries Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd's earnings momentum is Monitoring.
- PAT YoY Growth: +44%
Is Sudarshan Pharma Industries Ltd undervalued?
Sudarshan Pharma Industries Ltd's valuation metrics
- Margin of Safety: -51% (appears overvalued)
What are the revenue and margin trends for Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd's revenue and margin trends
- Revenue YoY: +45%
What sector does Sudarshan Pharma Industries Ltd belong to?
Sudarshan Pharma Industries Ltd key facts
- Sector: Trading
Is Sudarshan Pharma Industries Ltd a good deep value opportunity to study?
Sudarshan Pharma Industries Ltd shows limited deep value signals currently — score is 30/100 (Weak). Monitor for improvement.
- Value Score: 30/100 (Weak)
What is the bull and bear case for Sudarshan Pharma Industries Ltd?
Risk Factors (Bear Case)
- Appears overvalued despite underperformance
Which other Trading stocks are deep value opportunities?
Other deep value stocks in Trading
- Adani Enterprises Ltd — Score 42/100, Average, earnings accelerating
- State Trading Corporation of India Ltd — Score 37/100, Weak
How does the Trading sector look for deep value?
Trading deep value sector overview
- 2 deep value stocks in this sector
- Average value score: 36/100
- Avg PAT acceleration: -42.0pp
- Top pick: Adani Enterprises Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd has 3 key growth catalysts identified from recent earnings analysis
- Debt reduction plan execution (Q4 FY26)
- Margin recovery from operational improvements (Q1-Q2 FY27)
- Strategic investor entry (Q2 FY27)
What are the key risks in Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd has 3 key risks worth monitoring
- Debt spiral risk
- Structural margin pressure
- Working capital trap
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.